Royalty Pharma Plc Working Capital to Net Assets Ratio
Royalty Pharma Plc working capital to net assets ratio. Royalty Pharma Plc (RPRX) has a Working Capital to Net Assets ratio of 9.0% as of March 2026. Working capital of $890.13 Million (current assets of $1.43 Billion minus current liabilities of $535.68 Million) is measured against net assets of $9.94 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Royalty Pharma Plc (2014–2025)
Working capital to net assets ratio of Royalty Pharma Plc from 2014 to 2025. This chart shows how Royalty Pharma Plc's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of March 2026, the ratio stands at 9.0%, reflecting working capital of $890.13 Million against net assets of $9.94 Billion USD. Explore RPRX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Royalty Pharma Plc Working Capital to Net Assets Ratio by Year (2014–2025)
Royalty Pharma Plc working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Royalty Pharma Plc from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Royalty Pharma Plc's balance sheet.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -0.2% | $-17.21 Million | $9.71 Billion | $619.00 Million | $636.21 Million | ▼ -5.5 pp |
| 2024 | 5.3% | $548.52 Million | $10.34 Billion | $1.80 Billion | $1.25 Billion | ▼ -5.7 pp |
| 2023 | 11.0% | $1.11 Billion | $10.08 Billion | $1.27 Billion | $161.38 Million | ▼ -3.5 pp |
| 2022 | 14.6% | $1.39 Billion | $9.53 Billion | $2.55 Billion | $1.17 Billion | ▼ -11.8 pp |
| 2021 | 26.4% | $2.71 Billion | $10.25 Billion | $2.88 Billion | $171.25 Million | ▲ +10.5 pp |
| 2020 | 16.0% | $2.39 Billion | $14.97 Billion | $2.70 Billion | $307.89 Million | ▲ +7.8 pp |
| 2019 | 8.1% | $498.65 Million | $6.14 Billion | $832.07 Million | $333.42 Million | ▼ -36.4 pp |
| 2018 | 44.6% | $2.03 Billion | $4.55 Billion | $2.61 Billion | $580.17 Million | ▼ -12.8 pp |
| 2017 | 57.4% | $2.56 Billion | $4.47 Billion | $2.95 Billion | $383.41 Million | ▼ -3.3 pp |
| 2016 | 60.7% | $2.71 Billion | $4.46 Billion | $3.00 Billion | $297.32 Million | ▲ +2.6 pp |
| 2015 | 58.1% | $2.73 Billion | $4.70 Billion | $3.04 Billion | $314.39 Million | ▼ -41.8 pp |
| 2014 | 99.9% | $43.98 Million | $44.02 Million | $46.91 Million | $2.92 Million | — |